Aurinia Pharmaceuticals Inc. (AUPH) — closed signal from November 4, 2025
Partial Published before the outcome was known, scored automatically when the window closed on February 2, 2026.
Predicted vs. what happened
What happened
Reached 19% of the predicted growth at its peak, without hitting the target.
The thesis — published November 4, 2025
Aurinia's stock jumped quickly, and buying activity is much heavier than usual, with the recent average price climbing fast. Moves like this can cool off, and news adds extra risk. A report about an FDA official leaving stirred speculation and trading. Prefer buying on dips and waiting for proof the price can hold. The next 0-3 months may be bumpy, then improve if Lupkynis sales trends stay steady.
Primary drivers
- Strong recent price strength; recent average price is rising quickly
- News about an FDA official leaving boosted attention and trading
- Steady progress selling the Lupkynis medicine to more patients
- Unusually heavy trading shows many buyers active right now
How it played out
AUPH: target was not reached
Lyra published AUPH at $15.89 on 2025-11-04, with expected growth of 22%. The thesis pointed to strong recent price strength, a fast-rising recent average price, unusually heavy trading, attention from news about an FDA official leaving, and steady progress selling Lupkynis to more patients. It also warned that the next 0-3 months may be bumpy.
Inside the 2025-11-04 to 2026-02-02 window, AUPH peaked at $16.54 on 2025-12-23, a 4.1% gain. That stayed below the $19.39 target. It never got there. The stock ended at $14.53. The published thesis missed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.